Merck & Co. Inc. (MRK)

82.29
NYSE : Health Technology
Prev Close 82.95
Day Low/High 82.02 / 83.45
52 Wk Low/High 52.83 / 83.17
Avg Volume 11.84M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 214.11B
EPS 2.30
P/E Ratio 35.45
Div & Yield 2.20 (2.42%)

Latest News

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in...

Merck And NGM Bio Announce Extension Of Broad, Multi-Year Strategic Collaboration To 2022

Merck And NGM Bio Announce Extension Of Broad, Multi-Year Strategic Collaboration To 2022

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc.

New Treatment Option Now Available In Canada For Newly Diagnosed Patients With Advanced Lung Cancer

New Treatment Option Now Available In Canada For Newly Diagnosed Patients With Advanced Lung Cancer

KEYTRUDA ® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared to Chemotherapy Alone Every day, approximately 78 Canadians are diagnosed with lung cancer and 58 die from it i Non-small cell...

Digging Down on the Dow 30

Digging Down on the Dow 30

Just 13 of the 30 Dow components are in clear uptrends.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Chemotherapy For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the...

Merck Becomes #3 Most Shorted Dow Stock, Replacing MMM

Merck Becomes #3 Most Shorted Dow Stock, Replacing MMM

The most recent short interest data has been released for the 02/28/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Jim Cramer: Now We've Got FOBS, Fear of Big Sellers

Why are big institutions running and can you outrace them?

Merck Prices $5.0 Billion Debt Offering

Merck Prices $5.0 Billion Debt Offering

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced a $5.

Merck Begins Tender Offer To Acquire Immune Design

Merck Begins Tender Offer To Acquire Immune Design

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design (NASDAQ: IMDZ).

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) For Six-Week Dosing Schedule Across All Current Monotherapy Indications

European Medicines Agency Adopts Positive Opinion For Merck's KEYTRUDA® (pembrolizumab) For Six-Week Dosing Schedule Across All Current Monotherapy Indications

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new extended dosing schedule for...

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of...

Merck Becomes #4 Most Shorted Dow Stock, Replacing Visa

Merck Becomes #4 Most Shorted Dow Stock, Replacing Visa

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

LYNPARZA® (olaparib) Reduced The Risk Of Disease Progression Or Death As First-Line Maintenance Treatment In Germline BRCA-Mutated Metastatic Pancreatic Cancer

LYNPARZA® (olaparib) Reduced The Risk Of Disease Progression Or Death As First-Line Maintenance Treatment In Germline BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 POLO trial.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Immune Design Corp.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Immune Design Corp.

NEW YORK, Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp.

Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale Of Immune Design Corp.; Are Immune Design Shareholders Getting A Fair Deal?

Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale Of Immune Design Corp.; Are Immune Design Shareholders Getting A Fair Deal?

SAN DIEGO, Feb. 21, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immune Design Corp.

Merck To Acquire Immune Design

Merck To Acquire Immune Design

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.

Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial

Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial

Merck shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration.

Merck Provides Update On KEYNOTE-240, A Phase 3 Study Of KEYTRUDA® (pembrolizumab) In Previously Treated Patients With Advanced Hepatocellular Carcinoma

Merck Provides Update On KEYNOTE-240, A Phase 3 Study Of KEYTRUDA® (pembrolizumab) In Previously Treated Patients With Advanced Hepatocellular Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced...

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Node(s) Following Complete Resection

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Node(s) Following Complete Resection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) Reduced Risk Of Death By Nearly Half Compared To Sunitinib As First-Line Treatment For Advanced Renal Cell Carcinoma (RCC)

KEYTRUDA® (pembrolizumab) In Combination With Inlyta® (axitinib) Reduced Risk Of Death By Nearly Half Compared To Sunitinib As First-Line Treatment For Advanced Renal Cell Carcinoma (RCC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Inlyta (axitinib), a...

Merck Increases Focus On Advanced Prostate Cancer, Expanding Immuno-Oncology Program With Three New Phase 3 Trials

Merck Increases Focus On Advanced Prostate Cancer, Expanding Immuno-Oncology Program With Three New Phase 3 Trials

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with various agents for...

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing demand for its key cancer treatments.

Merck Becomes #5 Most Shorted Dow Stock, Replacing International Business Machines

Merck Becomes #5 Most Shorted Dow Stock, Replacing International Business Machines

The most recent short interest data has been released for the 01/31/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck Highlights Breadth Of Immuno-Oncology Research Program In Genitourinary Cancers At ASCO GU

Merck Highlights Breadth Of Immuno-Oncology Research Program In Genitourinary Cancers At ASCO GU

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from the company's broad immuno-oncology research program in genitourinary cancers - renal, prostate and bladder − will be...

Stocks Mixed Ahead of U.S.-China Trade Talks; Healthcare Sector Weighs on Dow

Stocks Mixed Ahead of U.S.-China Trade Talks; Healthcare Sector Weighs on Dow

The Dow Jones Industrial Average falls as investors eye progress in this week's renewed U.S.-China trade talks.

TheStreet Quant Rating: A+ (Buy)